BAVA:VIE
Bavarian Nordic A/S
€31.50
arrow_downward
-0.63%(-0.20) 1D
Oct 14, 5:36:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
€31.66
High
€31.74
Low
€31.38
Mkt. cap
2.77B
Avg. vol.
17.00
Volume
0.00
52-wk high
€32.47
52-wk low
€22.96
No. of employees
2K
Open
€31.66
High
€31.74
Low
€31.38
Mkt. cap
2.77B
Avg. vol.
17.00
Volume
0.00
52-wk high
€32.47
52-wk low
€22.96
No. of employees
2K
News stories
From web sources and news partners
marketscreener.com
·
48 minutes ago
Stocks end lower as hot inflation data stirs rate-hike worries
Stocktwits
·
11 minutes ago
S&P 500, Nasdaq See Worst Day In Over Two Months As Chipmaker Rout Deepens, CPI Data Comes In Hot — AAPL, SPCX, DRAM, SOXX In Focus
RealMoney Pro
·
1 hour ago
Hotter Inflation and AI Weakness End the S&P 500’s Run Without a 1% Drop
TradingView
·
3 hours ago
The Dow Jones Index Closes 0.18% Lower
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com